Qiagen (NYSE:QGEN) Stock Price Target Raised at Robert W. Baird

Qiagen (NYSE:QGEN) had its price target boosted by investment analysts at Robert W. Baird from $50.00 to $52.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 3.95% from the company’s current price.

Several other equities research analysts have also issued reports on QGEN. Berenberg Bank set a $45.50 price objective on Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. JPMorgan Chase & Co. raised their price target on Qiagen from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Morgan Stanley reiterated an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. Finally, Barclays set a $40.00 price objective on Qiagen and gave the stock an “equal weight” rating in a report on Friday, August 7th. Five analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Qiagen presently has an average rating of “Hold” and a consensus target price of $44.68.

Qiagen Trading Up 2.3%

Shares of QGEN stock opened at $50.02 on Thursday. The company has a 50 day moving average of $44.15 and a 200-day moving average of $40.51. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. Qiagen has a 12-month low of $32.53 and a 12-month high of $57.81. The firm has a market cap of $10.31 billion, a P/E ratio of 20.19, a PEG ratio of 4.87 and a beta of 0.61.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The business had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. Qiagen’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amundi lifted its stake in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after acquiring an additional 524,959 shares during the period. State Street Corp boosted its holdings in shares of Qiagen by 4.5% during the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock valued at $85,363,000 after buying an additional 93,575 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Qiagen by 20.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock worth $66,649,000 after buying an additional 286,665 shares during the period. Swiss National Bank grew its position in shares of Qiagen by 21.1% in the 1st quarter. Swiss National Bank now owns 716,059 shares of the company’s stock worth $28,686,000 after buying an additional 124,920 shares during the period. Finally, Arbejdsmarkedets Tillaegspension increased its stake in shares of Qiagen by 24.8% in the 1st quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company’s stock worth $25,502,000 after acquiring an additional 126,405 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.